WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H525709
CAS#: 109376-83-2
Description: ML 7 is a myosin light chain kinase inhibitor. ML 7 has been shown to protect cardiac function from ischemia/reperfusion (I/R) injury.
Hodoodo Cat#: H525709
Name: ML 7
CAS#: 109376-83-2
Chemical Formula: C15H18ClIN2O2S
Exact Mass: 451.98
Molecular Weight: 452.738
Elemental Analysis: C, 39.79; H, 4.01; Cl, 7.83; I, 28.03; N, 6.19; O, 7.07; S, 7.08
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ML-7; ML7; ML 7
IUPAC/Chemical Name: 1-((5-iodonaphthalen-1-yl)sulfonyl)-1,4-diazepane hydrochloride
InChi Key: KDDALCDYHZIZMH-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H17IN2O2S.ClH/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19,20)18-10-3-8-17-9-11-18;/h1-2,4-7,17H,3,8-11H2;1H
SMILES Code: O=S(N1CCNCCC1)(C2=C3C=CC=C(I)C3=CC=C2)=O.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 452.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Zhou Y, Zhang S, Deng S, Dai C, Tang S, Yang X, Li D, Zhao K, Xiao X. ML-7 amplifies the quinocetone-induced cell death through akt and MAPK-mediated apoptosis on HepG2 cell line. Toxicol Mech Methods. 2016 Jan;26(1):11-21. doi: 10.3109/15376516.2015.1090513. Epub 2015 Oct 8. PubMed PMID: 26446980.
2: Cherlet M, Gleich S, Dewerchin H, Nauwynck H, Daminet S, De Backer P, Croubels S. Quantitative analysis of an anti-viral immune escape compound ML-7 in feline plasma using ultra performance liquid chromatography/electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Sep 15;905:118-26. doi: 10.1016/j.jchromb.2012.08.014. Epub 2012 Aug 15. PubMed PMID: 22925719.
3: Lin HB, Cadete VJ, Sawicka J, Wozniak M, Sawicki G. Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia-reperfusion injury. J Proteomics. 2012 Sep 18;75(17):5386-95. doi: 10.1016/j.jprot.2012.06.016. Epub 2012 Jun 28. PubMed PMID: 22749930.
4: Rosenthal R, Choritz L, Schlott S, Bechrakis NE, Jaroszewski J, Wiederholt M, Thieme H. Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. Exp Eye Res. 2005 Jun;80(6):837-45. PubMed PMID: 15939040.
5: Odani K, Kobayashi T, Ogawa Y, Yoshida S, Seguchi H. ML-7 inhibits exocytosis of superoxide-producing intracellular compartments in human neutrophils stimulated with phorbol myristate acetate in a myosin light chain kinase-independent manner. Histochem Cell Biol. 2003 May;119(5):363-70. Epub 2003 May 16. PubMed PMID: 12750906.
6: Tian B, Brumback LC, Kaufman PL. ML-7, chelerythrine and phorbol ester increase outflow facility in the monkey Eye. Exp Eye Res. 2000 Dec;71(6):551-66. PubMed PMID: 11095907.
7: Järvelä K, Kööbi T, Kauppinen P, Kaukinen S. Effects of hypertonic 75 mg/ml (7.5%) saline on extracellular water volume when used for preloading before spinal anaesthesia. Acta Anaesthesiol Scand. 2001 Jul;45(6):776-81. PubMed PMID: 11421840.
8: Kelley SJ, Thomas R, Dunham PB. Candidate inhibitor of the volume-sensitive kinase regulating K-Cl cotransport: the myosin light chain kinase inhibitor ML-7. J Membr Biol. 2000 Nov 1;178(1):31-41. PubMed PMID: 11058685.
9: Matsuoka I, Nakahata N, Nakanishi H. Selective inhibition of collagen-induced arachidonic acid liberation by 1-(5-iodonaphthalene-1-sulphonyl)-1H-hexahydro-1,4-diazepine hydrochloride (ML-7), a myosin light chain kinase inhibitor, in washed rabbit platelets. Biochem Pharmacol. 1997 Nov 1;54(9):1019-26. PubMed PMID: 9374423.
10: Ohkubo S, Nakahata N, Ohizumi Y. ML-7 and W-7 facilitate thromboxane A2-mediated Ca2+ mobilization in rabbit platelets. Eur J Pharmacol. 1996 Mar 7;298(2):175-83. PubMed PMID: 8867106.
11: Isemura M, Mita T, Satoh K, Narumi K, Motomiya M. Myosin light chain kinase inhibitors ML-7 and ML-9 inhibit mouse lung carcinoma cell attachment to the fibronectin substratum. Cell Biol Int Rep. 1991 Oct;15(10):965-72. PubMed PMID: 1773444.
